PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1065207
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1065207
According to SPER Market Research, the peptide synthesis market estimated to reach USD 908 million by 2030 with a CAGR of 6.5%. Global burden of chronic disorders is increasing. The rising therapeutic applications of peptides for various chronic diseases are driving the growth of this market.
The COVID-19 pandemic has boosted the investments in research and development of peptide-based vaccines. The unique features of peptides such as specificity, selectivity has attracted pharmaceutical and biotechnology companies to bring peptide drug delivery systems to forefront. The advances in peptide therapeutics have increased the demand for reagents and equipment for peptide production.
AAPPTec, Advanced Chemtech, AmbioPharm Inc., AnyGen Co., Ltd., Aurigene Pharmaceutical Services Ltd., Bachem Holding AG, Bio-Synthesis Inc., Biotage AB, CEM Corporation, ChemPep Inc., Corden Pharma International, CPC Scientific Inc., CSBio, Dalton Pharma Services, GenScript Biotech Corporation, JPT Peptide Technologies GmbH, Kaneka Corporation, Luxembourg Bio Technologies Ltd., Merck KGaA, Mesa Laboratories inc., ProteoGenix, Purolite Pvt Ltd., Syngene International Ltd., Thermo Fisher Scientific, Vivitide.
Peptides are used as pharmaceutical drugs for various therapeutic areas due to their wide range of biological functions. Peptides can be effectively utilized in the treatment of cancer, obesity and diabetes. Demand for peptides is increasing for cardiovascular, renal and neurodegenerative disorders due to high biological activity, low toxicity, high specificity, easy synthesis, easy availability and large chemical space. The number of clinical trials for peptides is expected to increase in the forecast period.
Peptides based drug molecules fall between small and large biologic molecule size range. The regulatory framework designed for small and large biologics do not apply exactly same for peptides. Similarly, the regulatory challenges also appear in terms of functionality as most peptides have similar process of synthesis but have wide range of applications. The regulatory framework to cater all the diversities of this therapeutic category is not available and this restraint the growth of the peptide synthesis market. The guidelines of different regulatory bodies are also conflicting due to differences. A set of unified regulations is required for the production and marketing of peptides.
Personalized therapies are gaining interest for the better safety and patient care. Proteomic analysis can be used to characterize the molecular profiles of tissues. Personalized proteomics if applied, can help in providing better personalized treatment due to the clarity of pathomechanisms of a disease in a patient. The rise in the prevalence of diseases and side effects of medicines creates the urgent demand for personalized medicines. This rise in demand can provide growth opportunities to this market.
Peptides are sensitive to gastric environment and show low absorption. Therefore, most of the peptide therapeutics are administered via parenteral route of administration. The long-term treatment of peptides can become inconvenient and patient incompliant. When peptides are taken orally, they show low bioavailability due to enzymatic degradation and poor penetration across intestinal mucosa. However, parenteral administration shows better availability of peptides.
Based on end user, the market is segmented into Pharmaceutical & Biotechnology companies, CDMOs & CROs, Academic & Research Institutes. Pharmaceutical & Biotechnology companies hold the largest share of this market by end user segment due to growth pf peptide therapeutics industry.
North America owns the largest share of this market owing to rising research and development in life sciences, rising prevalence of chronic disorders, increasing demand for personalized therapies, rising interest in genomics and proteomics and growing investments in structure-based drug design development.